切换至 "中华医学电子期刊资源库"
高级检索
中华细胞与干细胞杂志(电子版)

中华细胞与干细胞杂志(电子版) ›› 2023, Vol. 13 ›› Issue (02) : 87 -92. doi: 10.3877/cma.j.issn.2095-1221.2023.02.004

综述

间充质干细胞治疗炎性关节炎的研究进展
冯星, 靳洪涛, 马隽, 宋永周, 刘爱京†()   
  1. 050000　石家庄，河北医科大学第二医院风湿免疫科
    050000　石家庄，河北医科大学解剖教研室；050000　石家庄，河北省干细胞医学转化工程研究中心
    050000　石家庄，河北医科大学第二医院骨科；050000　石家庄，河北省干细胞医学转化工程研究中心
    050000　石家庄，河北医科大学第二医院风湿免疫科；050000　石家庄，河北省干细胞医学转化工程研究中心
  • 收稿日期:2021-11-14 出版日期:2023-04-01
  • 通信作者: 刘爱京

Progress in the treatment of inflammatory arthritis with mesenchymal stem cells

Xing Feng, Hongtao Jin, Jun Ma, Yongzhou Song, Aijing Liu†()   

  1. Department of Rheumatology and Immunology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
    Department of Anatomy, Hebei Medical University, Shijiazhuang 050000, China; Hebei Stem Cell Medical Transformation Engineering Research Center, Shijiazhuang 050000, China
    Department of Orthopedics, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China; Hebei Stem Cell Medical Transformation Engineering Research Center, Shijiazhuang 050000, China
    Department of Rheumatology and Immunology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China; Hebei Stem Cell Medical Transformation Engineering Research Center, Shijiazhuang 050000, China
  • Received:2021-11-14 Published:2023-04-01
  • Corresponding author: Aijing Liu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

冯星, 靳洪涛, 马隽, 宋永周, 刘爱京. 间充质干细胞治疗炎性关节炎的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(02): 87-92.

Xing Feng, Hongtao Jin, Jun Ma, Yongzhou Song, Aijing Liu. Progress in the treatment of inflammatory arthritis with mesenchymal stem cells[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(02): 87-92.

炎性关节炎（IA）是一组可累及多关节的慢性炎症性疾病，包括强直性脊柱炎、类风湿关节炎和银屑病关节炎等，早期诊断和治疗对患者预后尤为关键。目前临床主要治疗药物以非甾体类抗炎药、缓解病情抗风湿药以及靶向合成药物为主，但仍有部分患者存在疗效差、易复发和副作用大的问题。近年来，间充质干细胞（MSCs）因来源广泛、易获取、分化能力强、免疫调节及抗炎等优点被越来越多应用于IA的治疗。本文对MSCs治疗IA的作用机制、来源、剂量、给药方式和疗效等进行综述，旨在为IA的治疗提供新思路。

关键词: 炎性关节炎, 间充质干细胞, 细胞治疗

Inflammatory arthritis (IA) is a group of chronic inflammatory diseases that influence multiple joints, including ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, and so on. And early diagnosis and treatment are critical for the prognosis of patients. Currently, non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, and biological agents are the main clinical drugs. However, some patients still suffer from poor efficacy, recurrence, and side effects. In recent years, mesenchymal stem cells (MSCs) have been increasingly applied in treating IA due to their advantages, such as various sources, easy access, strong differentiation potential, and immunomodulatory and anti-inflammatory abilities. This article reviewed the mechanisms, sources, dosages, administration methods, and efficacy of MSCs in treating IA, aiming to provide new ideas for the treatment of IA.

Key words: Inflammatory arthritis, Mesenchymal stem cells, Cell therapy
表1 纳入文献的基本特征
IA病种 第一作者 样本量 MSCs种类 输注方式 输注次数 随访时间 疗效 不良反应
AS Li [20] 5 UC-MSCs 静脉注射 1 ~ 3次 1年 有效 一过性轻微发热
AS 曲海洪[21] 30 UC-MSCs 局部注射 1次 6个月 有效 无
RA合并AS 王黎明[22] 2 UC-MSCs 静脉+局部注射 1次 4 ~ 14个月 有效 无
RA álvaro-Gracia [28] 53 AD-MSCs 静脉注射 3次 6个月 有效 感染、发热、腔隙性脑梗死等
RA Ghoryani [29] 9 BM-MSCs 静脉注射 1次 12个月 有效 无
PSA De Jesus [43] 1 AD-MSCs 静脉注射 2次 12个月 不明显 无
PSA Coutts [44] 1 UC-MSCs 静脉+关节腔注射 2次 12个月 有效 流感样症状
SLE关节炎 朱宁[50] 18 UC-MSCs 静脉注射 2次 3个月 有效 无
SLE关节炎 白茹[51] 10 UC-MSCs 静脉注射 3 ~ 5次 3年 有效 输注过程中发热、呕吐
JIA Swart [59] 6 BM-MSCs 静脉注射 1 ~ 2次 3个月 有效 无
JIA Wang [60] 10 UC-MSCs 静脉注射 2次 2年 有效 无
1
Poudel P, Goyal A, Bansal P, et al. Inflammatory arthritis[M]. StatPearls, 2020.
2
Sewerin P, Brinks R, Schneider M, et al. Prevalence of rheumatoid arthritis and spondyloarthritis in turkey: a nationwide study[J]. Arch Rheumatol, 2017, 33(2):128-136.
3
潘显阳. 痛风性关节炎发病的炎性机制研究进展[J]. 安徽医科大学学报, 2021, 56(7):1167-1171.
4
Hansildaar R, Vedder D, Baniaamam M, et al. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout[J]. Lancet Rheumatol, 2021, 3(1):e58-e70.
5
Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics[J]. Expert Rev Clin Immunol, 2020, 16(2):207-228.
6
Pistoia V, Raffaghello L. Mesenchymal stromal cells and autoimmunity[J]. Int Immunol, 2017, 29(2):49-58.
7
Yagyu T, Yasuda S, Nagaya N, et al. Long-term results of intracardiac mesenchymal stem cell transplantation in patients with cardiomyopathy[J]. Circ J, 2019, 83(7):1590-1599.
8
Pixley JS. Mesenchymal stem cells to treat type 1 diabetes[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(4):165315. doi: 10.1016/j.bbadis.2018.10.033.
9
Deng L, Peng Q, Wang H, et al. Intrathecal injection of allogenic bone marrow-derived mesenchymal stromal cells in treatment of patients with severe ischemic stroke: study protocol for a randomized controlled observer-blinded trial[J]. Transl Stroke Res, 2019, 10(2):170-177.
10
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement[J]. Cytotherapy, 2006, 8(4):315-317.
11
Han Y, Li X, Zhang Y, et al. Mesenchymal stem cells for regenerative medicine[J]. Cells, 2019, 8(8):886. doi: 10.3390/cells8080886.
12
Magatti M, Vertua E, De Munari S, et al. Human amnion favours tissue repair by inducing the M1-to-M2 switch and enhancing M2 macrophage features[J]. J Tissue Eng Regen Med, 2017, 11(10):2895-2911.
13
Magatti M, Vertua E, Cargnoni A, et al. The immunomodulatory properties of amniotic cells: the two sides of the coin[J]. Cell Transplant, 2018, 27(1):31-44.
14
Yang X, Yang J, Li X, et al. Bone marrow-derived mesenchymal stem cells inhibit T follicular helper cell in lupus-prone mice[J]. Lupus, 2018, 27(1):49-59.
15
Khosravi M, Bidmeshkipour A, Moravej A, et al. Induction of CD4+CD25+Foxp3+ regulatory T cells by mesenchymal stem cells is associated with RUNX complex factors[J]. Immunol Res, 2018, 66(1):207-218.
16
MacDonald GI, Augello A, De Bari C. Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases[J]. Arthritis Rheum, 2011, 63(9):2547-2557.
17
Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells[J]. Blood, 2007, 110(10):3499-3506.
18
Cosenza S, Toupet K, Maumus M, et al. Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis[J]. Theranostics, 2018, 8(5):1399-1410.
19
Fu X, Liu G, Halim A, et al. Mesenchymal stem cell migration and tissue repair[J]. Cells, 2019, 8(8):784. doi: 10.3390/cells8080784.
20
Li A, Tao Y, Kong D, et al. Infusion of umbilical cord mesenchymal stem cells alleviates symptoms of ankylosing spondylitis[J]. Exp Ther Med, 2017, 14(2):1538-1546.
21
曲海洪, 李晓昊, 张军. 不同剂量脐带间充质干细胞在针刀镜下定植治疗强直性脊柱炎患者病变髋关节的临床观察[J]. 国际感染杂志（电子版）, 2019, 8(2):67-69.
22
王黎明, 周建军, 白雯, 等. 脐带间充质干细胞治疗17例类风湿性关节炎患者的临床疗效观察[J]. 中国免疫学杂志, 2017, 7:659-662.
23
François RJ, Neure L, Sieper J, et al. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor beta in three more advanced cases[J]. Ann Rheum Dis, 2006, 65(6):713-720.
24
Xie Z, Wang P, Li J, et al. MCP1 triggers monocyte dysfunctions during abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis[J]. J Mol Med (Berl), 2017, 95(2):143-154.
25
米汝佳, 蔡兆鹏, 苏鸿君, 等. 肿瘤坏死因子α对强直性脊柱炎患者间充质干细胞成骨分化的影响[J]. 免疫学杂志, 2020, 36(3):254-259.
26
Calabresi, E, Petrelli F, Bonifacio AF, et al. One year in review 2018: pathogenesis of rheumatoid arthritis[J]. Clin Exp Rheumatol, 2018, 36(2):175-184.
27
Liu L, Wong CW, Han M, et al. Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritis[J]. EBioMedicine, 2019, 47:563-577.
28
álvaro-Gracia JM, Jover JA, García-Vicuña R, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial[J]. Ann Rheum Dis, 2017, 76(1):196-202.
29
Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J, et al. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: a successful clinical trial in Iran[J]. Biomed Pharmacother, 2019, 109:1834-1840.
30
Feng Z, Zhai Y, Zheng Z, Yang L, et al. Loss of A20 in BM-MSCs regulates the Th17/Treg balance in Rheumatoid Arthritis[J]. Sci Rep, 2018, 8(1):427. doi: 10.1038/s41598-017-18693-0.
31
Zheng J, Zhu L, Iok In I, et al. Bone marrow-derived mesenchymal stem cells-secreted exosomal microRNA-192-5p delays inflammatory response in rheumatoid arthritis[J]. Int Immunopharmacol, 2020, 78:105985. doi: 10.1016/j.intimp.2019.105985.
32
Zhang Q, Li Q, Zhu J, et al. Comparison of therapeutic effects of different mesenchymal stem cells on rheumatoid arthritis in mice[J]. PeerJ, 2019, 7:e7023. doi: 10.7717/peerj.7023.
33
侯婧瑛, 于萌蕾, 郭天柱, 等. 缺氧预处理激活HIF-1α/MALAT1/VEGFA通路促进骨髓间充质干细胞生存和血管再生[J]. 中国组织工程研究, 2021, 25(7):985-990.
34
Ankrum JA, Dastidar RG, Ong JF, et al. Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids[J]. Sci Rep, 2014, 4:4645. doi: 10.1038/srep04645.
35
Gossec L,Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update[J]. Ann Rheum Dis, 2020, 79(6):700 712.
36
Chandran V, Schentag CT, Brockbank JE, et al. Familial aggregation of psoriatic arthritis[J]. Ann Rheum Dis, 2009, 68(5):664-667.
37
Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene[J]. Am J Hum Genet, 2006, 78(5):827-851.
38
Brewerton DA, Caffrey M, Nicholls A, et al. HL-A 27 and arthropathies associated with ulcerative colitis and psoriasis[J]. Lancet, 1974, 1(7864):956-8.
39
Qian Y, Liu C, Hartupee J, et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease[J]. Nat Immunol, 2007, 8(3):247-256.
40
杨琴,张改连,温晓婷,等.银屑病关节炎治疗新进展[J].中华风湿病学杂志, 2020, 24(01):64-67.
41
王方迪,侯瑞霞,赵新程,等.银屑病患者血清对真皮间充质干细胞基因表达及功能的影响[J].中国免疫学杂志, 2021, 37(15):1867-1871.
42
Castro-Manrreza ME, Bonifaz L, Castro-Escamilla O, et al. Mesenchymal stromal cells from the epidermis and dermis of psoriasis patients: morphology, immunophenotype, differentiation patterns, and regulation of T cell proliferation[J]. Stem Cells Int, 2019, 2019:4541797. doi: 10.1155/2019/4541797.
43
De Jesus MM, Santiago JS, Trinidad CV, et al. Autologous adipose-derived mesenchymal stromal cells for the treatment of psoriasis vulgaris and psoriatic arthritis: A case report[J]. Cell Transplant, 2016, 25(11):2063-2069.
44
Coutts M, Soriano R, Naidoo R, et al. Umbilical cord blood stem cell treatment for a patient with psoriatic arthritis[J]. World J Stem Cells, 2017, 9(12):235-240.
45
Braiteh F, Hymes SR, Giralt SA, et al. Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma[J]. J Clin Oncol, 2008, 26(27):4511-4513.
46
桑雨婷,朱芸,马晶晶,等.银屑病关节炎患者皮损进展与血清总IgE及IL-6、TNF-α水平的关系[J]. 中国现代医生, 2020, 58(3):12-15.
47
Zoma A. Musculoskeletal involvement in systemic lupus erythematosus[J]. Lupus, 2004, 13(11):851-853.
48
Drenkard C, Bao G, Dennis G, et a1.The burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States[J]. Arthritis Care Res (Hoboken), 2014, 66(6):878-887．
49
耿研,李伯睿,张卓莉.系统性红斑狼疮患者有症状关节病变的肌肉骨骼超声特点[J]. 北京大学学报（医学版）, 2020, 52(1):163-168.
50
朱宁,毛静,张小莲,等.脐带间充质干细胞移植在系统性红斑狼疮患者中的应用研究[J].疑难病杂志, 2016, 15(1):44-47.
51
白茹,戚燕,吕昭萍,等.脐带间充质干细胞移植治疗难治性系统性红斑狼疮3年随访[J].中国免疫学杂志, 2017, 33(6):905-909.
52
中华医学会风湿病学分会,中国医院协会临床新技术应用专业委员会.异体间充质干细胞治疗系统性红斑狼疮专家共识[J].中华风湿病学杂志, 2022, 26(1):1-8.
53
Yuan X, Qin X, Wang D, et al. Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients[J]. Nat Commun, 2019, 10(1):2498. doi: 10.1038/s41467-019-10491-8.
54
丁会玲. 脐带间充质干细胞联合利妥昔单抗治疗系统性红斑狼疮临床研究[J]. 临床研究, 2016, 24(7):10-11.
55
Li D, Li X, Duan M,et al. MiR-153-3p induces immune dysregulation by inhibiting PELI1 expression in umbilical cord-derived mesenchymal stem cells in patients with systemic lupus erythematosus[J]. Autoimmunity, 2020, 53(4):201-209.
56
Cheng RJ, Xiong AJ, Li YH, et al. Mesenchymal stem cells: allogeneic MSC may be immunosuppressive but autologous MSC are dysfunctional in lupus patients[J]. Front Cell Dev Biol, 2019, 7:285. doi: 10.3389/fcell.2019.00285.
57
Martini A, Ravelli A, Avcin T, et al. Pediatric Rheumatology International Trials Organization (PRINTO). Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization International Consensus[J]. J Rheumatol, 2019, 46(2):190-197.
58
Marzetti V, Breda L, Miulli E, et al. Clinical characteristics of juvenile idiopathic arthritis in an area of central Italy: a population-based study[J]. Ann Ig, 2017, 29(4):281-292.
59
Swart JF, de Roock S, Nievelstein RAJ, et al. Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients[J]. Rheumatology, 2019, 58(10):1812-1817.
60
Wang L, Zhang Y, Li H, et al. Clinical observation of employment of umbilical cord derived mesenchymal stem cell for juvenile idiopathic arthritis therapy[J]. Stem Cells Int, 2016, 2016:9165267. doi: 10.1155/2016/9165267.
61
Orczyk K, Smolewska E. Are we right to consider mesenchymal stem cells to be a new perspective for patients with juvenile idiopathic arthritis?[J]. Arch Immunol Ther Exp (Warsz), 2018, 66(4):267-271.
[1] 沈纵, 魏晨如, 朱邦晖, 包郁露, 伍国胜, 孙瑜. 间充质干细胞治疗吸入性损伤的动物实验研究进展[J]. 中华损伤与修复杂志(电子版), 2023, 18(02): 180-183.
[2] 唐英俊, 李华娟, 王赛妮, 徐旺, 刘峰, 李羲, 郝新宝, 黄华萍. 人脐带间充质干细胞治疗COPD小鼠及机制分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 476-480.
[3] 李晔, 何洁, 胡锦秀, 王金祥, 田川, 潘杭, 陈梦蝶, 赵晓娟, 叶丽, 张敏, 潘兴华. 高活性间充质干细胞干预猕猴卵巢衰老的研究[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 210-219.
[4] 龙慧玲, 林蜜, 邵婷. 三维球体间充质干细胞培养技术的研究进展及其应用[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 229-234.
[5] 刘文慧, 吴涛, 张曦. 间充质干细胞联合血小板生成素受体激动剂在异基因造血干细胞移植后血小板恢复中的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 242-246.
[6] 王红敏, 谢云波, 王彦虎, 王福生. 间充质干细胞治疗新冠病毒感染的临床研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 247-256.
[7] 秦富豪, 郑正, 江滨. 间充质干细胞在克罗恩病肛瘘治疗中的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(03): 172-177.
[8] 袁久莉, 刘丹, 李林藜, 刘晋宇. 毛囊间充质干细胞的基础研究及临床应用[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(03): 189-192.
[9] 雷双银, 习剑鑫, 贺羽轩, 姚静宜, 石博雅, 马杰, 池光范, 李美英. 间充质干细胞源外泌体在神经退行性疾病治疗中的应用与进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(02): 93-100.
[10] 符莞孟, 王晓黎, 刘玉, 张潍, 张菊. 干细胞治疗多囊卵巢综合征的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(02): 108-114.
[11] 陈玉婷, 周影, 陆雅斐, 江滨. 缺氧预处理间充质干细胞的功能及机制研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(02): 115-120.
[12] 杨蕴钊, 周诚, 石美涵, 赵静, 白雪源. 人羊水间充质干细胞对膜性肾病大鼠的治疗作用[J]. 中华肾病研究电子杂志, 2023, 12(04): 181-186.
[13] 宋艳琪, 任雪景, 王文娟, 韩秋霞, 续玥, 庄凯婷, 肖拓, 蔡广研. 间充质干细胞对顺铂诱导的小鼠急性肾损伤中细胞铁死亡的作用[J]. 中华肾病研究电子杂志, 2023, 12(04): 187-193.
[14] 陈客宏. 干细胞外泌体防治腹膜透析腹膜纤维化新技术研究[J]. 中华肾病研究电子杂志, 2023, 12(03): 180-180.
[15] 梁宇同, 丁旭, 马国慧, 黄艳红. 间充质干细胞在宫腔粘连治疗中的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(05): 596-599.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号